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Background: Copy number variations (CNVs) of chromosomal region 22q11.2 are associated with a subset of patients
with congenital heart disease (CHD). Accurate and efficient detection of CNV is important for genetic analysis of CHD.
The aim of the study was to introduce a novel approach named CNVplex®, a high-throughput analysis technique
designed for efficient detection of chromosomal CNVs, and to explore the prevalence of sub-chromosomal imbalances
in 22q11.2 loci in patients with CHD from a single institute.
Results: We developed a novel technique, CNVplex®, for high-throughput detection of sub-chromosomal copy
number aberrations. Modified from the multiplex ligation-dependent probe amplification (MLPA) method, it introduced
a lengthening ligation system and four universal primer sets, which simplified the synthesis of probes and significantly
improved the flexibility of the experiment. We used 110 samples, which were extensively characterized with chromosomal
microarray analysis and MLPA, to validate the performance of the newly developed method. Furthermore, CNVplex® was
used to screen for sub-chromosomal imbalances in 22q11.2 loci in 818 CHD patients consecutively enrolled from
Shanghai Children’s Medical Center. In the methodology development phase, CNVplex® detected all copy number
aberrations that were previously identified with both chromosomal microarray analysis and MLPA, demonstrating
100% sensitivity and specificity. In the validation phase, 22q11.2 deletion and 22q11.2 duplication were detected in
39 and 1 of 818 patients with CHD by CNVplex®, respectively. Our data demonstrated that the frequency of 22q11.2
deletion varied among sub-groups of CHD patients. Notably, 22q11.2 deletion was more commonly observed in cases
with conotruncal defect (CTD) than in cases with non-CTD (P < 0.001). With higher resolution and more probes against
selected chromosomal loci, CNVplex® also identified several individuals with small CNVs and alterations in other
chromosomes.
Conclusions: CNVplex® is sensitive and specific in its detection of CNVs, and it is an alternative to MLPA for batch
screening of pathogenetic CNVs in known genomic loci.
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Copy number variation (CNV) of DNA sequences is a
source of genetic variation and has an important role in
the genetics of complex disease. Analysis of CNV in dis-
eases has led to the identification of novel disease-causing
mutations and increasingly offers important new insights
into the genetics of these disorders [1,2].
The chromosome region 22q11.2 is a hotspot for gen-
omic rearrangement and related disorders. Aberrations
of this region are among the most common constitutional
chromosomal abnormalities [3]. Patients with 22q11.2
deletion demonstrate a broad spectrum of clinical phe-
notypes. Congenital heart disease (CHD) is the most
frequently observed clinical manifestation, occurring in
three-quarters of patients with 22q11.2 deletion [4].
Long-term studies carried out in several research centers
indicate that children with CHD are most likely to
undergo examinations for CNVs on chromosome 22q11.2
[5]. The results of such genetic testing are important for
clinical decision makers because patients with 22q11.2 de-
letion need early medical intervention. Meanwhile, a more
detailed study on the mechanism of interaction between
multiple genes is important to understand the exact cause
of the 22q11 deletion syndrome [6].
When studying CNV-associated human diseases, accur-
ate and efficient CNV genotyping is one of the key steps.
Many techniques have been widely applied in CNV stud-
ies, such as fluorescence in situ hybridization, comparative
genomic hybridization arrays (CGH), quantitative real-
time PCR, and multiplex ligation-dependent probe
amplification (MLPA). These assays rely on either array-
or PCR-based methods and offer different degrees of
resolution, precision, and throughput [7]. All methods
have advantages and limitations in different settings.
In this paper, we present a new approach named
CNVplex® for the detection of chromosomal alterations
using CNVs in the 22q11.2 region as a test model. This
technique can analyze up to 160 gene loci in a single array.
In our report, 157 loci along the 22q11.2 region and other
chromosomes whose defects led to a 22q11.2 deletion
syndrome-like clinical entity were analyzed simultaneously.
The performance of CNVplex® was evaluated using samples
with and without known CNVs on chromosome 22 that
were previously characterized by chromosomal microarray
analysis (CMA) and MLPA. The assay was then applied in
a clinical setting in subjects with CHD, which is a popula-
tion that is highly enriched for 22q11.2 deletion.
Methods
Cohorts
First, 110 cases, which were previously extensively char-
acterized by CMA and MLPA, were used to evaluate the
performance of CNVplex®. Next, 818 patients with at
least one congenital heart defect were enrolled fromNovember 2011 to January 2014 in Shanghai Children’s
Medical Center (Table 1). A cardiologist confirmed the
CHD diagnosis for all patients by reviewing and evaluat-
ing patient history, physical examinations, and medical
records. Patients with mild CHD abnormalities, e.g., iso-
lated patent ductus arteriosus, atrial/ventricular septal
defect, or patent foramen ovale, were excluded. The pa-
tients were divided into two groups: conotruncal heart
defect (CTD) (n = 615) and non-CTD (n = 203). All sub-
jects were unrelated, and the median age at the time of
diagnosis was 10 months with a range of 3 days to 18 years.
Peripheral blood samples of all cases were obtained, and
genomic DNA was extracted using the QIAmp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) with standard
protocols. The DNA quality was tested by optical density
(OD) 260/280 nm ratios, quantified by ultraviolet spectro-
photometry, and stored at −20°C until use. Written con-
sent was obtained from parents or guardians of all
patients. This study was approved by the Ethics Com-
mittee of Shanghai Children’s Medical Center.
CNVplex®
CNVplex® is based on the MLPA method, and a sche-
matic of the experimental principle and workflow of this
technique is illustrated in Figure 1 [8].
Similar to MLPA, each array of CNVplex® contains sev-
eral pairs of probes. Each probe consists of a hybridization
oligonucleotide that is complementary to the target and
the universal PCR primer sequence to allow PCR amplifi-
cation with the fluorescent primer pairs. The downstream
probe of MLPA has a stuffer sequence with variable length
to generate the unique length of ligated probes, and these
probes are too long to be chemically synthesized [9].
CNVplex® uses the locus discrimination linker sequence
with short length so chemically synthesized oligonucleo-
tides can be used for all probes. However, the use of syn-
thetic oligonucleotides limits the length of the probes. To
bypass these limitations, CNVplex® introduces a lengthen-
ing ligation system, which contains an input template and
a pair of lengthening ligation probes. Each probe contains
a sequence that is complementary to the input template
sequence, and these two probes can hybridize immediately
adjacent to each other without a gap. After hybridization,
the probes specific to human genomic DNA and the input
template are ligated at the same time by a thermally stable
ligase enzyme. The PCR primers subsequently amplify the
double-ligated probes exponentially, which become a sin-
gle contiguous molecule. This structure supersedes the
stuffer sequence in MLPA, which ensures that the size of
all probes is within 72 bp and that all probes are commer-
cially available.
In addition, to increase the number of probes that can
be used, we designed four types of 5’ universal primers
labeled with different fluorophores and two types of 3’
Table 1 Prevalence of 22q11.2 deletions in patients with CHD
Cardiac phenotypes Total subjects 22q11.2 deletion subjects Subjects frequency (%)
Conotruncal cardiac defects
Tetralogy of Fallot 231 20 8.7
Pulmonary atresia/Ventricular septal defect 135 17 12.6
Double outlet right ventricle 115
Transposition of great arteries 91
Tricuspid atresia 20
Persistent truncus arteriosus 12 1 8.3
Interrupted aortic arch 11
Non-conotruncal cardiac defects
Single atrium/Single ventricle 58
Atrioventricular septal defect 59
Total anomalous pulmonary venous connection 30 1 3.3
Partial anomaly of pulmonary venous connection 14
Subvalvular aortic stenosis 16
Coarctation of the aorta 15
Others 11
Total 818 39 4.8
Atrioventricular septal defect involved complete, partial and transitional atrioventricular septal defect. Others involved Aortopulmonary window and
Cor triatriatum.
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3’ probe and lengthening ligation probe to amplify the li-
gated products. The discrimination of probes was four-
fold higher using the four-color probe sets and allowed 96
probes to be used in a single PCR. Amplification products
were separated by size and color using capillary electro-
phoresis, and the relative amount of PCR product was
proportional to the amount of target sequence (Figure 1).
In our project, ligation products of each sample were sub-
sequently amplified in two PCRs. In this way, we were able
to combine 192 probes in a ligation reaction. Excluding
the probes that served as controls, 160 loci could be ana-
lyzed simultaneously in a single assay.
Using synthetic oligonucleotides, 189 probes were se-
lected in this study including 157 target-specific probes
and 32 reference probes. For the 22q11 region, 115 probe
pairs against 46 genes distributed in a genomic region of
7.5 Mb were designed. In addition, probes against other
sub-chromosomal regions were synthesized and formatted
into the analysis, including 4 loci on 22q13, 8 loci on
4q35, 6 loci on chromosome 8, 6 loci on chromosome 9,
10 loci on chromosome 10, and 8 loci on chromosome 17.
Thirty-two reference probes were designed to target se-
quences located in different sub-chromosomal loci that
have not been reported to have any copy number poly-
morphism. The sizes of the PCR fragments and target loci
sequences in each reaction are listed in Additional file 1.
Reagents in our research for the denaturation, ligation,
and subsequent PCR amplification were purchased fromGenesky Diagnostics (Suzhou, China) and Takara (Dalian,
China). First, 150 ng of genomic DNA in 8 μL of volume
was denatured for 6 min at 98°C and then immediately
put on ice. Hybridization and ligation were performed for
about 15 h (5 cycles of 94°C for 1 min and 60°C for 3 h)
by adding 4 μL probe mix and 8 μL ligation mix (5.8 μL
water, 2 μL 10× ligation buffer, and 0.2 μL Taq DNA
ligase). After inactivating the enzyme for 2 min at 94°C,
20 μL EDTA (20 mM) was added when the temperature
reached 72°C. The subsequent PCR was prepared in 20 μL
for each sample and contained 10 μL 2× PCR Master Mix,
1 μL primer mix, 7.8 μL water, and 1.2 μL ligation prod-
uct. The PCR program was as follows: 95°C for 2 min;
5 cycles of 94°C for 20 s, 65°C reduced by 1°C per cycle
for 40 s, and 72°C for 1.5 min; 27 cycles of 94°C for 20 s,
60°C for 40 s, and 72°C for 1.5 min; and 68°C for 60 min.
The PCR products were diluted 10-fold and denatured for
5 min at 95°C before being run by capillary electrophoresis
using an ABI 3130XL genetic analyzer(Applied Biosystems
Inc., Foster City, CA, USA), and the raw data were ana-
lyzed by GeneMapper 4.1 (Applied Biosystems). In
CNVplex®, peak ratios between 0.75 and 1.25 are con-
sidered normal. Ratios above 1.25 indicate the presence
of a gain of the target sequence while ratios below 0.75
indicate a loss of the target sequence.
MLPA
We used a commercial SALSA P250-B1 kit (MRC-Holland,
Amsterdam, The Netherlands) for the MLPA assay. The
Figure 1 A diagram of CNVplex® technology. Two reference loci (R1/R2) and four target genomic segments (T1–T4) with various copy numbers
are illustrated in this figure. They are mixed with probes, denatured, and annealed under certain conditions. The 5’ probes contain oligonucleotides
specific to 5’ universal primers, and the 3’ probes include a locus discrimination linker sequence (LDLS) and oligonucleotides complementary to 3’
universal primers. Each pair of the probes contains a hybridization oligonucleotide that is specific to the human genomic DNA and can hybridize
immediately adjacent to each other without a gap. The lengthening ligation system, which consists of a pair of lengthening ligation probes and a
certain input template, is shown as orange lines. The probes are specific to the input template sequence and can hybridize to the template. After
hybridization, probes specific to human genomic DNA and the input template are ligated at the same time using a thermally stable ligase enzyme.
The PCR primers subsequently amplify the double-ligated probe, which becomes a single contiguous molecule. Amplicons with different sizes are
separated by capillary electrophoresis, and the peak heights of samples are calculated and subsequently normalized to reference segments. Using
LDLSs of various length and four 5’ universal primers labeled with a different fluorescent dye, CNVplex® allows 96 loci to be detected in a single PCR.
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cludes 30 that hybridize to chromosome 22q11 and the
remaining 18 control probes are located on 22q13, 10p15,
8p23, 4q34-qter, 9q34.3, and 17p13.3. All procedures were
carried out according to the manufacturer’s protocol, and
data were visualized and analyzed with GeneMaker
software (SoftGenetics, LLC, State College, PA, USA).
A threshold of the peak ratio change of <0.70 was usedto identify potential deletions, and a threshold of >1.30
was used to identify potential duplications.
CMA
A genomic hybridization was performed on each sample
with the CytoScan HD array (Affymetrix, Santa Clara,
CA). All arrays were labeled, hybridized, and processed
in the Microarray Core Facility at Shanghai Children’s
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manufacturer. After scanning, the resulting intensity files
were visualized and analyzed with the Chromosome
Analysis Suite software package (Affymetrix). The results
were evaluated using UCSC Genome Browser March
2009 (NCBI37/hg19).
Real-time PCR
Primers in our research were designed with Primer3
software (Table 2). All of the selected sequences were
aligned against the human genome using the BLAT pro-
gram to ensure specific hybridization. A total of 1 μL
(100 ng/μL) genomic DNA was amplified in a reaction
mixture containing 12.5 μL ExTaq (Takara), 0.4 μM each
primer, 3.3 μM SYTO9 fluorescent dye (Life technologies,
Carlsbad, CA, USA), and water to a total volume of 25 μL.
Cycling conditions were 94°C for 30 s and then 45 cycles
of 94°C for 5 s and 60°C for 34 s. Real-time quantitative
PCR was performed on the Rotor-Gene Q (Qiagen) detec-
tion system. The expression level of target genes was nor-
malized to the HMBS housekeeping gene. Each experiment
was run in triplicate for each subject, and copy number al-
terations were calculated according to the 2-△△CT method.
Statistical analysis
All statistical analysis was performed with the SPSS 17.0
statistical software package. The frequencies of 22q11.2
deletion in patients in the CTD and non-CTD groups
were compared with Fisher’s exact test. To assess the as-
sociation of small CNVs identified in our report with
CHD, we compared the frequencies of these CNVs be-
tween the case and control cohorts. The control cohort
was assembled from a previously published study on the
distribution and characteristics of CNVs in Asian popu-
lations. A P value less than 0.05 in a two-sided test was
considered significant throughout this paper.
Results
Performance of CNVplex®
The 110 patients used in this study were initially charac-
terized by CMA and MLPA. Using these tests, 9 of theTable 2 Primers used for real-time PCR








TOP3B-R TGGCACTGAAAAGAGACTGCpatients (Table 3) had 22q11 CNVs, and the other 101
patients were negative. We evaluated the performance of
CNVplex® in the detection of selected genomic region
CNVs with these extensively characterized samples. All
nine of the previously identified 22q11 CNVs were de-
tected by this method, and no false-positive results were
yielded in the remaining 101 samples, indicating 100%
sensitivity and specificity.
Furthermore, we used the peak area from 10 normal
samples without copy number alterations and 6 patients
with 22q11.2 deletion to evaluate the signal consistency
of the CNVplex® method. The coefficient of variability
(CV) of the relative peak area for each oligo pair (Additional
file 2) was calculated with the following formula: CV =
standard deviation/average value. All probes showed a CV
ratio ≤ 0.1, passing the threshold of the variability test and
further demonstrating the low variance of the method.
CNVs detected by CNVplex® in a large cohort of CHD
The utility of CNVplex® to detect selected genomic copy
number aberrations in clinical molecular diagnostic set-
tings was further tested in a large cohort of patients with
CHD. Pathogenic 22q11.2 deletions were detected in 39 of
818 patients with CHD, which included 22q11.2 duplica-
tion in 1 patient, small variants of uncertain significance
(VUS) in 20 patients, and sub-chromosomal copy number
aberrations in genomic loci other than 22q11 in 5 patients.
Chromosome 22q11.2 is a well-characterized genomic
region that contains multiple region-specific low-copy
repeats (LCRs). Eight LCR clusters (LCR22A–H) are lo-
cated in the proximal 22q region. For 39 patients with
22q11.2 microdeletion, the majority (34/39, 87%) shared
the typical deletion flanked by LCR22A and LCR22D,
spanning approximately 2.57 Mb. Three patients (3/39,
8%) had a 1.34-Mb proximally nested deletion spanning
LCR22A to LCR22B, and two patients (2/39, 5%) had an
atypical deletion covering LCR22A to LCR22C with a
length of about 2 Mb. However, the duplication that we
identified in this study using the CNVplex® technique
extended distally (spanning from LCR22E to LCR22H)





Table 3 The results detected by MLPA, CMA, and CNVplex®
Laboratory results
MLPA CMA CNVplex®
P1 chr22:19171011-21351601 loss chr22:18648866-21465659 loss chr22:18893757-21464055 loss
P2 chr22:19171011-21351601 loss chr22:18916842-21798907 loss chr22:18893757-21464055 loss
P3 chr22:19171011-21351601 loss chr22:18916842-21798907 loss chr22:18893757-21464055 loss
P4 chr22:19171011-21351601 loss chr22:18648866-21465659 gain chr22:18893757-21464055 loss
P5 chr22:19171011-21351601 loss chr22:18916842-21465662 loss chr22:18893757-21464055 loss
P6 chr22:22312856-22330186 gain chr22:22311348-22578983 gain chr22:22312856-22330186 gain
P7 chr22:19171011-21351601 loss chr22:18916842-21800797 loss chr22:18893757-21464055 loss
chr22:22312856-22330186 gain chr22:22311348-22578983 gain chr22:22312856-22330186 gain
P8 chr22:19171011-21351601 loss chr22:18916842-21798907 loss chr22:18893757-21464055 loss
P9 chr22:19171011-21351601 loss chr22:18916842-21041014 loss chr22:18893757-20940053 loss
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pherograms of the 22q11.2 deletion, 22q11.2 duplication,
and normal sample are presented in Additional files 3
and 4, respectively. Using CNVplex®, we could precisely
identify the breakpoints for each deletion. All deletions
had a proximal breakpoint between markers USP18 and
DGCR6. Similarly, cases flanked distally by LCR22B had
a breakpoint between RTN4R and ZNF74, whereas the
deletion flanked by LCR22C had a breakpoint between
MED15 and PI4KA (Figure 2).
Furthermore, CNVplex® identified two VUS, including
a 25-kb region containing the DGCR6 and PRODH
genes and a segment with TOP3B, respectively (Figure 2).
Interestingly, 9 of 818 CHD patients harbored copyFigure 2 Summary of 22q11.2 copy number variations (CNVs) identified by
showing the locations of low-copy repeats of chromosome 22 (LCR22s) (ye
build 37). Genes that had probes in CNVplex® are shown in red boxes, and th
(MLPA) are shown in blue boxes. Solid red and blue bars below the map depnumber aberrations in DGCR6/PRODH (7 deletions and 2
duplications), and 11 individuals had duplications in
TOP3B.
For five patients, there were obvious changes in the
probes outside the 22q11 region. There were three imbal-
ances (two deletions and one duplication) at 4q35 and one
deletion at 22q13. We also identified a complex copy
number aberration at 8p23 locus in one patient, including
a 10.4-Mb microdeletion immediately followed by a 2.75-
Mb microduplication.
Results of confirmatory tests
Although there is a growing interest in the identification
of CNVs, there is not a universal gold standard that isCNVplex®. A schematic representation of the physical map of 22q11.2
llow boxes) and sequence position (UCSC version hg19, based on NCBI
ose that had probes in multiplex ligation-dependent probe amplification
ict the deletions and duplication identified in this study, respectively.
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ical molecular diagnostic settings. The positive cases that
were identified in our report were further confirmed by
MLPA, CMA, or real-time PCR (Figure 3). MLPA was
performed on all positive cases. CMA was used to con-
firm CNVs located on other chromosomes. Real-time
PCR was performed for the regions that were too small
to be detected by commercial MLPA kits.
For patients with pathogenic 22q11.2 CNVs, MLPA
confirmed all of the results obtained by CNVplex®
(Figure 2). However, MLPA was not optimal for cases
with small CNVs because of the small number of probes
against the target sequences in the MLPA B250 kit
(Figure 3). For 20 patients with small CNVs, real-time
PCR was performed, and the results were consistent
with the copy number status ascertained by CNVplex®
analyses (Figure 4). For two of the five patients with
CNVs outside the 22q11 region, CMA testing was per-
formed to precisely assess the size of the altered region.
In one of the two patients analyzed with CNVs outside
the 22q11 region, a deletion at 4q35 revealed by
CNVplex® was confirmed by both CMA and MLPA, and
a hemizygous loss of four probes located in PPP1R3B
and MSRA and a gain in the signal of two probes in
GATA4 revealed by CNVplex® in the second patient was
confirmed by CMA and mapped to 8p23.3–23.1 (10.4 Mb)
and 8p23.1–p22 (2.75 Mb), respectively. Noticeably, MLPA
also had one reference probe on each of these genes, but
the probe on GATA4 had a signal of 1.285, which was
within the normal range (0.70–1.30); thus, the microdupli-
cation could be missed (Figure 5).
Assessment of clinical manifestation
The diagnosis information and clinical data of 818 pa-
tients with CHD are summarized in Table 1. The fre-
quency of CNVs varied between subgroups of patients
with cardiac defects. Microdeletion of 22q11.2 occurredFigure 3 Workflow of CNV detection and validation in 818 patients
with congenital heart disease.in 38 of 615 CTD patients (6.2%) and in 1 of 203 non-
CTD patients (0.5%), indicating that the 22q11.2 dele-
tion was more significantly enriched in cases with CTD
than in non-CTD cases (P < 0.001).
Discussion
Several advanced technology platforms have been fre-
quently used in genome-wide studies on CNVs, such as
CGH microarrays and next-generation sequencing. How-
ever, most of these technologies are costly, and they may
not be the first choice for CNV studies of a specific gene
or a few genetic loci of interest. Efficient and reliable CNV
assays for target regions are important for investigating
the roles of CNVs in human diseases [10]. MLPA provides
a multiplex assay for copy number measurement of target
DNA segments, and it has been widely used for studies on
genomic disorders. However, the current MLPA design
involves a long probe generated by cloning, which is a
time-consuming and costly process. Additionally, MLPA
is limited by the oligonucleotide length and its relatively
low throughput (at most 48 loci in the same amplifica-
tion reaction).
CNVplex® overcomes the intrinsic obstacles of MLPA
and offers several additional advantages. The lengthen-
ing ligation system allows all probes to be manufactured
by conventional oligonucleotide synthesis that circum-
vents the laborious step. By combining the four probe
sets (labeled with different fluorophores), this approach
effectively quadrupled the number of probes that can be
used in an available size range. Using a group of well-
characterized samples, we demonstrated that CNVplex®
was an efficient, highly reliable method with high sensi-
tivity and specificity. Further, using a cohort of CHD pa-
tients, we demonstrated the ability of the new method to
correctly detect gain or loss of genomic material, to de-
termine the candidate genes contributing to the disease,
and to delineate the extent of the region involved in the
rearrangement.
In the current study, CNVplex® detected common re-
current deletions (4.8% detection prevalence) in 39 indi-
viduals and a 22q11.2 duplication (0.1% duplication
prevalence) in one patient among 818 CHD patients.
Even though previous data suggested that the frequency
of the 22q11.2 duplication was lower than that of the de-
letions, the estimated frequency in our report was much
lower than that in other studies [11,12]. This may be
due to patient selection because patients with 22q11.2
duplication have a very wide range of phenotypic vari-
ability, and the cohort with CHD was not enriched for
22q11.2 duplication.
The data enabled us to provide the prevalence of
22q11.2 deletion in defined sub-populations registered
with CTD and non-CTD. Patients with CTD were more
likely to have 22q11.2 deletion than non-CTD cases,
Figure 4 Validation of small CNVs by real-time PCR. SYTO9 and primers specific to the DGCR6, PRODH, and TOP3B genes were used for detection
in patients (P1–P20) and control genomic DNA samples (C1–C3). The normalized gene copy number is expected to be N = 2, compared with N <
1.5 for gene deletion and N > 2.5 for duplication. The bar graph shows a 50% decrease in copy number (Y-axis) of the DGCR6/PRODH gene for patient
1 and 2 and a 33% increase (from two to three copies) for patient 3 to patient 9 (P3–P9) compared with the control samples (C1–C3). The red
bars indicate a gain of one copy number (duplication) of the TOP3B gene in 11 patients (P10–P20) compared with the control samples (C1–C3).
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when all CHD cases were considered, pulmonary atresia
(PA) was, together with ventricular septal defect (VSD),
the most frequent cardiac malformation in individuals
carrying the 22q11.2 deletion followed by tetralogy of
Fallot (TOF) and persistent truncus arteriosus (PTA).
This result was in line with the findings of previous
studies, which concluded that a high prevalence of the
deletion was noted in patients with TOF, PA/VSD, PTA,
interrupted aortic arch, and tricuspid atresia [13,14].
It is difficult for physicians to identify 22q11.2 deletion
syndrome with certainty because this syndrome shows a
wide variability in phenotype expression [15]. Additionally,
some characteristics such as speech difficulties and learn-
ing disabilities are not readily apparent during early infancy
[16]. Because CHD is generally the first presenting symp-
tom in such patients, molecular screening for 22q11.2 in
CHD patients is important in the evaluation of associated
noncardiac features [17]. The association of CTD with
22q11.2 deletion reminds us that it may be advisable to
test for the microdeletion when there is a diagnosis of con-
otruncal malformation, especially in young infants whose
extracardiac features cannot yet be excluded [18].In addition to CNVs identified in 22q11.2, the screen-
ing of related chromosomes whose defects led to a
22q11.2 deletion syndrome-like clinical entity was cru-
cial for CHD patients. CNVplex® uses 42 probes outside
22q11.2 according to the most-frequent chromosomal
findings to optimize the diagnostic protocol [19]. The
MLPA P250-B1 kit also targets those regions, but the
density of probes was low. To determine more regions
of interest, other MLPA kits were needed, which means
more genomic DNA input and cost. In many instances,
the users leave these probes out of the analysis process
or simply regard them as control probes [17]. One pa-
tient in our study had an alteration in chromosome 8p.
CNVplex® revealed a hemizygous loss and a subsequent
gain in signal. MLPA also had reference probes on these
genes, but the duplication of GATA4 was missed. The
high density of probes in CNVplex® allowed us to build
more stability and reliability into the test than MLPA.
With much higher multiplexing capability, CNVplex®
allowed more regions of interest to be scanned than
other methods, which may provide insight into the genes
or genomic regions that are crucial for specific phenotypic
manifestations. Multiple dosage-sensitive genes contribute
Figure 5 Chromosome 8 CNVs detected by chromosomal microarray, CNVplex® and MLPA. A. Microarray profile of chromosome 8 showing a
deletion at 8pter–8p23.1 and a duplication at 8p23.1–8p22. B. CNVplex® probes set in 8p and results inferred from the signal. Green boxes are
probes, and solid-colored bars below the map depict the results. C. Data of MLPA analysis. The dots represent MLPA probes, and the lines indicate
the threshold.
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One of these candidate genes is TBX1, whose haploinsuffi-
ciency is thought to be responsible for several phenotypes
of this syndrome [20]. In this study, two variations contain-
ing the DGCR6/PRODH and TOP3B genes were identified
in several individuals, and the variation in the former gene
was not detected by MLPA. Xu et al. 2011 [21] created a
database for common and rare CNVs in Asian populations.
We compared the frequency of CNVs identified in our pa-
tient group with that of published controls. The frequency
of DGCR6/PRODH CNVs in the patients (9 of 818 patients)
was significantly higher than that in controls (2 of 6,533individuals) (P < 0.001) and so was the duplication of
TOP3B (11 of 818 versus 3 of 6,533 individuals, P < 0.001).
Although there was no evidence for their relevance with
CHD, the increased allele frequency of these genes deserved
further discussion. It is likely that the identification of small
CNVs within 22q11.2 will greatly contribute to our under-
standing of these genes and further segregation of the
major regulatory genes.
In addition, using a higher density of probe sets,
CNVplex® analysis could more precisely delineate the
breakpoints of CNVs in selected genomic regions than
MLPA. More precise determination of the breakpoints
Zhang et al. BMC Genomics  (2015) 16:364 Page 10 of 11for CNVs had important implications in a study of dele-
tion mechanisms and explanations for the high frequency
of chromosome rearrangements in this region [22]. By
designing probes for the unique regions interspersed
within the segments containing the breakpoint region
for common 22q11.2 deletion, CNVplex® allows unprece-
dented opportunities to define the chromosome break-
points in individuals and to examine genotype–phenotype
relationships.
Conclusions
The lengthening ligation system and four color probe
sets allow CNVplex® to detect copy number alterations
of any region with higher resolution and lower cost than
other methods. The successful identification of CNVs in
previously well-characterized cases and CHD patients
further demonstrated it to be an efficient and reliable
technique. Additionally, multiple probes of CNVplex®
not only allow a more exact prediction of the alterations
but also make it possible to characterize typical and
atypical CNVs more accurately. This offers more infor-
mation than MLPA, which primarily elucidates the mo-
lecular basis of this disease and determines candidate
genes. We believe that the use of CNVplex® in more in-
dividuals will yield more information.
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